1. Home
  2. FEAM vs BLRX Comparison

FEAM vs BLRX Comparison

Compare FEAM & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FEAM
  • BLRX
  • Stock Information
  • Founded
  • FEAM 2016
  • BLRX 2003
  • Country
  • FEAM United States
  • BLRX Israel
  • Employees
  • FEAM N/A
  • BLRX N/A
  • Industry
  • FEAM Major Chemicals
  • BLRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FEAM Industrials
  • BLRX Health Care
  • Exchange
  • FEAM Nasdaq
  • BLRX Nasdaq
  • Market Cap
  • FEAM 71.5M
  • BLRX 15.3M
  • IPO Year
  • FEAM N/A
  • BLRX 2011
  • Fundamental
  • Price
  • FEAM $3.60
  • BLRX $4.45
  • Analyst Decision
  • FEAM Strong Buy
  • BLRX Strong Buy
  • Analyst Count
  • FEAM 2
  • BLRX 2
  • Target Price
  • FEAM $121.00
  • BLRX $19.00
  • AVG Volume (30 Days)
  • FEAM 12.7K
  • BLRX 252.1K
  • Earning Date
  • FEAM 05-15-2025
  • BLRX 08-14-2025
  • Dividend Yield
  • FEAM N/A
  • BLRX N/A
  • EPS Growth
  • FEAM N/A
  • BLRX N/A
  • EPS
  • FEAM N/A
  • BLRX N/A
  • Revenue
  • FEAM N/A
  • BLRX $22,340,000.00
  • Revenue This Year
  • FEAM N/A
  • BLRX N/A
  • Revenue Next Year
  • FEAM N/A
  • BLRX N/A
  • P/E Ratio
  • FEAM N/A
  • BLRX N/A
  • Revenue Growth
  • FEAM N/A
  • BLRX 91.68
  • 52 Week Low
  • FEAM $2.82
  • BLRX $2.30
  • 52 Week High
  • FEAM $31.51
  • BLRX $35.60
  • Technical
  • Relative Strength Index (RSI)
  • FEAM 33.46
  • BLRX 50.17
  • Support Level
  • FEAM $3.41
  • BLRX $3.79
  • Resistance Level
  • FEAM $3.85
  • BLRX $4.62
  • Average True Range (ATR)
  • FEAM 0.28
  • BLRX 0.56
  • MACD
  • FEAM -0.06
  • BLRX -0.13
  • Stochastic Oscillator
  • FEAM 15.24
  • BLRX 21.79

About FEAM 5E Advanced Materials Inc.

5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: